论文部分内容阅读
将真核表达载体EGFPN1, pCMVhIL-12, pCMVhGM-CSF, pCMVmIL-12和pCMVmGM-CSF分别导入减毒鼠伤寒沙门氏菌SL3261中, 扩增后经由胃管饲予BALB/c和C57BL/6小鼠, 6周后用Lewis肺癌细胞和4T1乳腺癌细胞对上述小鼠进行攻击. 在小鼠的肝脏、脾脏、肾脏、小肠和肿瘤等组织器官中均可观察到绿色荧光蛋白的表达和相应真核表达载体的整合. 小鼠血清中相应的细胞因子水平升高, CD8+/CD4+比率增大, 细胞免疫功能增强. 各实验组肿瘤的生长较对照组缓慢, 部分小鼠肿瘤消退, 小鼠生存时间明显延长. 该研究为减毒沙门氏菌作为口服基因治疗载体用于肿瘤的预防和治疗提供了实验依据.
The eukaryotic expression vectors EGFPN1, pCMVhIL-12, pCMVhGM-CSF, pCMVmIL-12 and pCMVmGM-CSF were introduced into attenuated Salmonella typhimurium SL3261, respectively, and were amplified and administered to BALB/c and C57BL/6 mice via gastric tube. After 6 weeks, these mice were challenged with Lewis lung cancer cells and 4T1 breast cancer cells. Expression of green fluorescent protein and corresponding eukaryotic expression were observed in the liver, spleen, kidney, small intestine, and tumor tissues of mice. The integration of the vector. The corresponding cytokine levels in the mouse serum increased, the CD8+/CD4+ ratio increased, and the cellular immune function was enhanced. The growth of the tumor in each experimental group was slower than that of the control group. Some of the mouse tumors subsided and the survival time of the mice was obvious. Extension. This study provides an experimental basis for the prevention and treatment of tumors by attenuated Salmonella as an oral gene therapy vector.